Trial Profile
A Randomized, Double-Blind, Active-Controlled, Parallel-Group, Multicenter Study to Determine the Efficacy and Safety of Albiglutide as Compared With Sitagliptin in Subjects With Type 2 Diabetes Mellitus With Renal Impairment.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 29 Aug 2023
Price :
$35
*
At a glance
- Drugs Albiglutide (Primary) ; Sitagliptin
- Indications Type 2 diabetes mellitus
- Focus Pharmacogenomic; Registrational; Therapeutic Use
- Acronyms Harmony-8
- Sponsors GlaxoSmithKline; GSK
- 27 Sep 2013 Results presented at the 49th Annual Meeting of the European Association for the Study of Diabetes.
- 25 Jun 2013 Results presented at the 73rd Annual Scientific Sessions of the American Diabetes Association.
- 24 Jun 2013 Results were presented at the American Diabetes Association Meeting (ADA), according to a GlaxoSmithKline media release.